Lilly (Eli) balance sheet
At the end of fiscal 2025, Lilly (Eli) had total assets of $112.48bn and shareholders' equity of $26.54bn. It held $7.27bn in cash against $42.50bn of debt: net debt of $35.23bn.
Balance sheet
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.5 | 6.0 | 5.9 | 4.0 | 3.8 | 3.9 | 3.7 | 4.6 | 6.5 | 7.3 | 2.3 | 3.7 | 3.8 | 2.1 | 2.8 | 3.3 | 7.3 | 4.9 |
| Receivables | 3.3 | 3.5 | 3.6 | 3.3 | 3.4 | 3.2 | 3.5 | 4.0 | 4.5 | 4.6 | 4.5 | 5.9 | 6.7 | 6.9 | 9.1 | 11.0 | 17.8 | 22.1 |
| Inventory | 2.8 | 2.5 | 2.3 | 2.6 | 2.9 | 2.7 | 3.4 | 3.6 | 4.5 | 3.1 | 3.2 | 4.0 | 3.9 | 4.3 | 5.8 | 7.6 | 13.7 | 18.2 |
| Total current assets | 12.5 | 14.8 | 14.2 | 13.0 | 13.1 | 11.9 | 12.6 | 15.1 | 19.2 | 20.5 | 13.7 | 17.5 | 18.5 | 18.0 | 25.7 | 32.7 | 55.6 | 65.3 |
| Goodwill | 1.2 | 1.4 | 1.4 | 1.5 | 1.5 | 1.8 | 4.0 | 4.0 | 4.4 | 1.4 | 3.7 | 3.8 | 3.9 | 4.1 | 4.9 | 5.8 | 5.9 | 9.9 |
| Total assets | 27.5 | 31.0 | 33.7 | 34.4 | 35.2 | 36.3 | 35.6 | 38.8 | 45.0 | 43.9 | 39.3 | 46.6 | 48.8 | 49.5 | 64.0 | 78.7 | 112.5 | 148.1 |
| Accounts payable | 1.0 | 1.1 | 1.1 | 1.2 | 1.1 | 1.1 | 1.3 | 1.3 | 1.4 | 1.2 | 1.4 | 1.6 | 1.7 | 1.9 | 2.6 | 3.2 | 5.4 | 5.8 |
| Total current liabilities | 6.6 | 6.9 | 8.9 | 8.4 | 8.9 | 9.7 | 8.2 | 11.0 | 14.5 | 11.9 | 11.8 | 12.5 | 15.1 | 17.1 | 27.3 | 28.4 | 35.2 | 47.0 |
| Short-term debt | −0.0 | 0.0 | 1.5 | 0.0 | 1.0 | 2.7 | 0.0 | 1.9 | 3.7 | 1.1 | 1.5 | 0.0 | 1.5 | 1.5 | 6.9 | 5.1 | 1.6 | 2.5 |
| Long-term debt | 6.6 | 6.8 | 5.5 | 5.5 | 4.2 | 5.3 | 8.0 | 8.4 | 9.9 | 9.2 | 13.8 | 16.6 | 15.3 | 14.7 | 18.3 | 28.5 | 40.9 | 47.0 |
| Total debt | 6.7 | 6.9 | 8.5 | 5.5 | 6.2 | 8.0 | 8.0 | 10.3 | 13.6 | 10.3 | 15.3 | 16.6 | 16.9 | 16.3 | 25.3 | 33.8 | 42.5 | 49.5 |
| Shareholders' equity | 9.5 | 12.4 | 13.5 | 14.8 | 17.6 | 15.4 | 14.6 | 14.0 | 11.6 | 9.8 | 2.6 | 5.6 | 9.0 | 10.6 | 10.8 | 14.3 | 26.5 | 40.3 |
| Net debt (negative = net cash) | 2.2 | 1.0 | 2.6 | 1.5 | 2.4 | 4.1 | 4.3 | 5.7 | 7.1 | 3.0 | 13.0 | 12.9 | 13.1 | 14.2 | 22.5 | 30.5 | 35.2 | 44.6 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 11.0 | 12.0 | 14.2 | 16.1 | 17.8 | 18.4 | 20.1 | 22.1 |
| Inventory | 7.6 | 9.3 | 11.0 | 12.2 | 13.7 | 14.5 | 16.8 | 18.2 |
| Total current assets | 32.7 | 41.3 | 49.9 | 62.1 | 55.6 | 54.8 | 64.7 | 65.3 |
| Goodwill | 5.8 | 5.8 | 5.8 | 5.9 | 5.9 | 6.1 | 8.8 | 9.9 |
| Total assets | 78.7 | 89.4 | 100.9 | 114.9 | 112.5 | 116.6 | 142.3 | 148.1 |
| Accounts payable | 3.2 | 3.4 | 4.1 | 4.3 | 5.4 | 5.0 | 6.1 | 5.8 |
| Total current liabilities | 28.4 | 30.1 | 39.0 | 40.1 | 35.2 | 36.6 | 47.7 | 47.0 |
| Short-term debt | 5.1 | 4.0 | 5.7 | 1.6 | 1.6 | 4.0 | 7.1 | 2.5 |
| Long-term debt | 28.5 | 34.5 | 34.2 | 40.9 | 40.9 | 39.4 | 47.9 | 47.0 |
| Total debt | 33.6 | 38.5 | 39.9 | 42.5 | 42.5 | 43.4 | 54.9 | 49.5 |
| Shareholders' equity | 14.3 | 15.8 | 18.3 | 23.8 | 26.5 | 31.2 | 33.9 | 40.3 |
Compare with peers
- Johnson & Johnson balance sheet
- Merck & Co. balance sheet
- Pfizer balance sheet
- Astrazeneca PLC balance sheet
- Bristol Myers Squibb balance sheet
Head to head: JNJ vs LLYLLY vs MRKLLY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies